Game-changing cancer therapy: Imugene’s VAXINIA receives FDA orphan drug status for bile tract cancer

By on    Pharma Industry News  

Game-changing cancer therapy: Imugene’s VAXINIA receives FDA orphan drug status for bile tract cancer

Imugene Limited has received a significant boost with the United States Food and Drug Administration (FDA) granting Orphan Drug Designation (ODD) to its experimental therapy, CF33-hNIS (VAXINIA), aimed at treating bile tract cancer. This designation propels Imugene’s clinical-stage oncolytic virotherapy forward, positioning the Sydney-based company as a key player in the development of innovative cancer […]

Imugene’s VAXINIA trial shows promising early results for solid tumours

By on    Pharma Industry News  

Imugene’s VAXINIA trial shows promising early results for solid tumours

Imugene Limited (ASX: IMU), a prominent player in the immuno-oncology field, has released an encouraging update on its Phase 1 MAST trial, which evaluates the safety and efficacy of the novel oncolytic virus, CF33-hNIS (VAXINIA), used both as monotherapy and in combination with pembrolizumab (KEYTRUDA). As the trial progresses, noteworthy outcomes are emerging, particularly in […]